Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this insightful session on understanding the multifaceted advantages of CDK4/6 inhibitors in HR+/HER2- breast cancer, as highlighted by the PALOMA-2 study. Frontline management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer has been revolutionized by the introduction of CDK4/6 inhibitors. These targeted therapies, when combined with endocrine therapy, have demonstrated significantly improved progression-free survival and overall response rates compared to endocrine therapy alone, offering patients a more effective and durable treatment option with a manageable side effect profile.
The PALOMA-2 study, specifically, provided compelling evidence for the efficacy of palbociclib, a CDK4/6 inhibitor, in this patient population. Its findings underscore the importance of incorporating these agents into initial treatment strategies, allowing for a personalized approach that optimizes patient outcomes and enhances quality of life from the very beginning. This paradigm shift in treatment not only extends the period of disease control but also minimizes the need for more aggressive treatments prematurely.
Therefore, get an overall knowledge on the understanding of the best practices in the treatment of HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
2.
Dementia-like protein buildup found in pancreas cells before cancer develops
3.
Radiotherapy after mastectomy can be avoided, study finds
4.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
Quality of Life Through Identity Reconstruction and Social Reintegration After Cancer Treatment
2.
Essential Updates in Hematology in Daily Practice
3.
Exploring the Latest Advances in PTLD Cancer Treatment
4.
Radiopharmaceutical Theranostics: Precision Radiation Delivered Through Molecular Targeting
5.
Clonal Hematopoiesis and Healthy Aging: Clinical Implications, Mechanisms, and Emerging Perspectives
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Understanding Iron Deficiency and Its Common Symptoms
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation